Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2021 08:00 ET | Source: Immutep Limited

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

Fast Track designation opens the potential for expedited development and review with the US FDAFast Track was granted based on the promising data package from Immutep, including from Immutep’s Phase...
April 07, 2021 08:00 ET | Source: Immutep Limited

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
March 17, 2021 08:00 ET | Source: Immutep Limited

Immutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual Conference

Sydney, AUSTRALIA, March 17, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
March 16, 2021 08:00 ET | Source: Immutep Limited

Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer

New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
March 09, 2021 08:00 ET | Source: Immutep Limited

IMMUTEP SECURES SECOND UNITED STATES PATENT GRANT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR

Sydney, AUSTRALIA, March 09, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
March 05, 2021 08:00 ET | Source: Immutep Limited

Immutep Expands Part B of TACTI-002 Study

Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
January 27, 2021 08:00 ET | Source: Immutep Limited

Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study

Independently reviewed safety run-in data prompts recommendation to initiate enrolment for the randomised portion of the Phase II EAT COVID studyUp to 110 COVID-19 patients to participate in...
January 21, 2021 18:03 ET | Source: Immutep Limited

Immutep Quarterly Activities Report

Highlights Encouraging efti data reported from phase IIb AIPAC and phase II TACTI-002 clinical trialsTACTI-002 study expanded in lung cancerNew phase II trial in head and neck cancer announcedEOC...
January 21, 2021 17:40 ET | Source: Immutep Limited

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
January 06, 2021 19:04 ET | Source: Immutep Limited

Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study

Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC)Recruitment of additional 1st line non small cell lung cancer (NSCLC) patients startedFurther interim data...